Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005 - Test2 - elhamkhani - TriplyDB

Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005

Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005

http://www.wikidata.org/entity/Q24656098

about

Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer Metabolism Emerging PSA-based tests to improve screening Recent developments in multivitamin/mineral research Overdiagnosis and overtreatment of prostate cancer Management of low (favourable)-risk prostate cancer Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates Loss of tumor suppressor mir-203 mediates overexpression of LIM and SH3 Protein 1 (LASP1) in high-risk prostate cancer thereby increasing cell proliferation and migration.Cancer incidence trends among Asian American populations in the United States, 1990-2008 Lung cancer stage at diagnosis: Individual associations in the prospective VITamins and lifestyle (VITAL) cohort.A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancer Prostate specific antigen testing in family practice: a cross sectional survey of self-reported rates of and reasons for testing participation and risk disclosure Men (aged 40-49 years) with a single baseline prostate-specific antigen below 1.0 ng/mL have a very low long-term risk of prostate cancer: results from a prospectively screened population cohort Focal therapy for prostate cancer: rationale and treatment opportunities.Focal therapy in the management of localized prostate cancer.Childhood body mass index and the risk of prostate cancer in adult men.Screening for prostate cancer: the debate continues Increasing detection of significant prostate cancer in younger men - ten year trends in prostate cancer risk profile in the Mid-West of Ireland.Evolution from active surveillance to focal therapy in the management of prostate cancer.Dietary fat intake in relation to lethal breast cancer in two large prospective cohort studies.Principles of cancer screening: lessons from history and study design issues.Cancer screening trials: nuts and bolts.Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.From bench to bedside: the realities of reducing global prostate cancer disparity in black men.Simulation optimization of PSA-threshold based prostate cancer screening policies.Is anyone listening? Variation in PSA screening among providers for men 75+ before and after United States Preventive Services Task Force recommendations against it: a retrospective cohort study.Prostate cancer susceptibility variants confer increased risk of disease progression.Reduced risk of prostate cancer in U.S. Men with AIDS.Role of human tissue kallikrein in gastrointestinal stromal tumour invasion.CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.Patient perspective on watchful waiting/active surveillance for localized prostate cancer.The REDUCE metagram: a comprehensive prediction tool for determining the utility of dutasteride chemoprevention in men at risk for prostate cancer.Expected population impacts of discontinued prostate-specific antigen screening.Gleason 6 Prostate Cancer: Translating Biology into Population Health.What is the true number needed to screen and treat to save a life with prostate-specific antigen testing?Cancer survivors in Switzerland: a rapidly growing population to care for.Men's perspectives on selecting their prostate cancer treatment Prostate cancer in East Asia: evolving trend over the last decade.New serum biomarkers for prostate cancer diagnosis.Fine mapping the KLK3 locus on chromosome 19q13.33 associated with prostate cancer susceptibility and PSA levels.

P2860

Q26774456-52CA2802-C8B4-42BC-8ED5-AC16058066F0 Q26828563-A6CA7436-8DC5-4512-A5DA-8D77247C791B Q26849381-92C994B0-8314-4C5F-BA5C-0E9D4D444469 Q26859596-FFB40C25-6A4F-4E29-AD66-C44132B17E00 Q26996501-165F9D5B-A998-4AF0-B5A7-A59DA11299F1 Q28251617-B6833692-744D-48C3-AB2C-E99E0715D7EA Q30009388-F404AFBB-80BD-4030-91BD-C431A381306C Q30542355-0C730B84-0D2C-4236-A005-18DE30D61D54 Q31016924-CE9331EC-86D2-44AD-B350-EEC62E3755AE Q33558289-C305AF8A-4192-4828-BF51-D4F5A9CAD734 Q33599365-644CE17F-2CBF-4F8C-897E-C3835067F254 Q33642527-D2246FB3-1B01-4E86-9152-C5F45831C40B Q33643656-D654E045-F9C0-4E04-87F3-0CA88A19457D Q33702259-1E893B55-441D-48E1-A736-805529DE77E4 Q33790382-E81C20EA-C242-4B11-88A5-F560DA98709A Q33877451-9E6A558E-F5CD-4A70-8FB9-3037B8A28C42 Q33885776-F883424C-8491-408A-892A-BE83A1B1AC4A Q33904126-7647ACA1-25E9-40E7-8852-6801AA4D4ACB Q33933490-8F98496B-3447-4E6C-8B1F-6015694289C1 Q34014487-A6CA65AC-3D45-449E-B17D-2A49AD837C28 Q34065705-770D86C0-9D30-417A-8A53-7BBDC4746E09 Q34073143-F8596D01-2353-48A9-A6DB-677AE0FEBA6B Q34130128-79E414EA-29D4-49DE-BA15-080BD969960E Q34135132-9256CAA1-76FB-4C45-8552-37276DA526D1 Q34149637-1F2DF88D-369B-4BFB-9E61-B545EC11B39A Q34160375-0D8D23A2-C36E-4D09-86FF-70E794EBB685 Q34175836-95E3E973-B533-4658-8FE0-69E4CC05FF9D Q34292990-2F63ED03-33FE-4B37-BFD6-A753F7F287A9 Q34344121-E5FD4379-5220-4E04-AC25-D18FE52976C8 Q34387852-D59F1AFB-F214-4CBF-97EB-A242115011AD Q34419421-CB64EAF0-2752-47E9-9AD9-C084AF68B6D9 Q34453917-F69F266D-9F1E-4457-8A35-04F96DAAC286 Q34458237-EBEA58E1-178E-4586-9C79-8698D21B3D6A Q34470640-1ECD96D1-93A4-4E5C-AA01-CCD2BE7B0EBB Q34679360-2B5C5788-61AF-4601-B5A1-8FF700A54C35 Q34771560-E4F11291-3C07-48A4-A83D-56D5937CD10A Q34817192-0DECF7C2-966D-46AC-9EFA-251A67996317 Q34927940-1F75D5F8-FA86-4C6A-BAAC-30E006575846 Q34939111-6C2BF512-FC12-4773-B3AC-305F3A8EC56F Q34975896-32674D91-EB95-46FA-8A03-CF4149E3242C

P2860

Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005

http://www.wikidata.org/entity/Q24656098

description

2009 nî lūn-bûn

@nan

2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Prostate cancer diagnosis and ...... c antigen screening: 1986-2005

@ast

Prostate cancer diagnosis and ...... c antigen screening: 1986-2005

@en

Prostate cancer diagnosis and ...... c antigen screening: 1986-2005

@nl

type

label

Prostate cancer diagnosis and ...... c antigen screening: 1986-2005

@ast

Prostate cancer diagnosis and ...... c antigen screening: 1986-2005

@en

Prostate cancer diagnosis and ...... c antigen screening: 1986-2005

@nl

prefLabel

Prostate cancer diagnosis and ...... c antigen screening: 1986-2005

@ast

Prostate cancer diagnosis and ...... c antigen screening: 1986-2005

@en

Prostate cancer diagnosis and ...... c antigen screening: 1986-2005

@nl

P1433

Q24656098-773874BF-6005-452D-9826-F7388A624F6E

P1476

Q24656098-D024A640-54CF-4484-BBC8-596D47791B27

P2093

Q24656098-17B94138-A967-440B-8C0D-0D818E601029

Q24656098-BA6D6E40-673B-48B4-94AA-825B27A9471E

P2860

Q24656098-11C41FDE-A939-44CD-802F-7103A923302D

Q24656098-218AE3F6-7D3E-4427-8EFA-520D1320A3E8

Q24656098-24FE3EBD-8B7A-4317-8AE3-4A69B901FA22

Q24656098-3035CD05-B65D-43D8-A977-3C336F4144F3

Q24656098-58E12E88-0232-4739-B420-372201F9BF60

Q24656098-6A360DB8-50B3-4929-8DAE-D4C19AEDE3A8

Q24656098-857EA210-AC39-4E05-B63B-6C4558EF3DCC

Q24656098-929BABFB-FAC7-46DE-A38D-41F20996C421

Q24656098-AB7B5F60-F763-499C-974A-E15D99A5236E

Q24656098-BA06099A-0625-41F4-B966-76B96AD22C7D

P304

Q24656098-E29AF3FC-9EE1-427D-8850-667C9638B333

P31

Q24656098-E9842F14-B6F2-420A-98B7-F525635A6788

P3181

Q24656098-AFFE8517-0830-47EA-B101-5CFB03EC2CC5

P356

Q24656098-205C8E04-DD7D-46A4-9A56-B0249A73F4C5

P407

Q24656098-44B3405D-7410-44CA-9871-900151A0AE64

P433

Q24656098-06B81A4C-D3E3-4305-8CC3-6A7B101F4E89

P478

Q24656098-719E04B3-40BD-4BEC-9BEF-C6667AD86633

P577

Q24656098-854FCD80-67F1-4CDA-9CBE-C168FF03B5AA

P5875

Q24656098-0B52E568-DAB0-4E0B-8ADA-CC870571CA1C

P698

Q24656098-BAACBFEF-9D97-4E3C-A4E0-24D0EB4B8FD3

P921

Q24656098-da3aa76e-67ea-4ec0-b274-286c993a514d

P932

Q24656098-FEECD4EF-267A-4EE2-9A33-A2CE45E03B91

P3181

P356

P1433

Journal of the National Cancer Institute

P1476

Prostate cancer diagnosis and ...... c antigen screening: 1986-2005

@en

P2093

H Gilbert Welch

http://www.w3.org/2001/XMLSchema#string

Peter C Albertsen

http://www.w3.org/2001/XMLSchema#string

P2860

Mortality results from a randomized prostate-cancer screening trial

Screening and prostate-cancer mortality in a randomized European study

Skin biopsy rates and incidence of melanoma: population based ecological study

The role of increasing detection in the rising incidence of prostate cancer.

Rate of over-diagnosis of breast cancer 15 years after end of Malmö mammographic screening trial: follow-up study.

Measurement of prostate-specific antigen in serum as a screening test for prostate cancer.

The natural history of invasive breast cancers detected by screening mammography

Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study

Clinical responses to undiluted and diluted smallpox vaccine.

Ramifications of screening for breast cancer: 1 in 4 cancers detected by mammography are pseudocancers.

P304

1325-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

446067

http://www.w3.org/2001/XMLSchema#string

P356

10.1093/JNCI/DJP278

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P577

2009-10-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26780612

http://www.w3.org/2001/XMLSchema#string

P698

19720969

http://www.w3.org/2001/XMLSchema#string

P921

P932

2758309

http://www.w3.org/2001/XMLSchema#string